Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports. Huang NS, Chen JY, Meng Y, Li QL, et al. Oral Oncol 2024;159:107014.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Huang NS, Chen JY, Meng Y, Li QL, et al. Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports. Oral Oncol 2024;159:107014.
PMID: 39306936